MANNHEIM, Germany I December 09, 2024 I Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to ...
PHILADELPHIA, PA, USA I 09, 2024 I GSK plc (LSE/NYSE: GSK) today announced statistically significant and clinically meaningful overall survival (OS) ...
ATHENS, GA & SAN JOSE, CA, USA I December 09, 2024 I CyanVac LLC, a clinical-stage biotechnology company developing intranasal vaccines using a transformational parainfluenza virus 5 (PIV5)-based ...
CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment ...
When combined with venetoclax and azacitidine (standard-of-care treatments for AML), STX-0712 improved therapeutic efficacy in 60% of patient samples by differential targeting both CCR2-positive ...
Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy ...
Data demonstrate dose dependent survival advantage with AUTX-703 in primary patient-derived orthotopic AML model ...
WEST CHESTER, PA, USA I 09, 2024 I Molecular Targeting Technologies, Inc. (MTTI) published preclinical study results for their proprietary ...